［1］Sun Y. Review and prospect of oncology drug therapy for 100 years［J］.Chin J Oncol, 2004, 26(11):701-703. ［孙燕.肿瘤药物治疗百年回顾与展望［J］.中华肿瘤杂志，2004，26（11）：701-703.］
［2］Curigliano G，Cardinale D，Dent S，et al.Cardiotoxicity of anticancer treatments：Epidemiology，detection，and management［J］.CA Cancer J Clin，2016，66(4)：309-325.
［3］Shi YK, Sun Y. Manual of medical oncology［M］. Beijing: People's Medical Publishing House, 2015：42.［石远凯，孙燕.临床肿瘤内科手册［M］.北京：人民卫生出版社，2015：42.］
［4］Lovett R，Kelly V，Goodall M.Cabazitaxel for metastatic hormone-relapsed prostate cancer treated with docetaxel［J］.Lancet Oncol，2016，17(7)：872-873.
［5］Nieuweboer AJ，De Graan AM，Hamberg P，et al.Effects of budesonide on cabazitaxel pharmacokinetics and cabazitaxel-induced diarrhea：A randomized，open-label multicenter phase Ⅱ study［J］.Clin Cancer Res，2017，23(7)：1679-1683.
［6］Genova C，Alama A，Coco S，et al.Vinflunine for the treatment of non-small cell lung cancer［J］.Expert Opin Investig Drugs，2016，25(12)：1447-1455.
［7］Oh IJ，Kim KS，Park CK，et al.Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma：A multi-center randomized phase Ⅲ trial［J］.BMC Cancer，2016，16：690.
［8］Van Der Velden DL，Opdam FL，Voest EE.TAS-102 for treatment of advanced colorectal cancers that are no longer responding to other therapies［J］.Clin Cancer Res，2016，22(12)：2835-2839.
［9］Arita S，Shirakawa T，Matsushita Y，et al.Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer［J］.Anticancer Res，2016，36(4)：1959-1966.
［10］Eckardt JR，Bentsion DL，Lipatov ON，et al.Phase Ⅱ study of picoplatin as second-line therapy for patients with small-cell lung cancer［J］.J Clin Oncol，2009，27(12)：2046-2051.
［11］Hager S，Ackermann CJ，Joerger M，et al.Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review［J］.Ann Oncol，2016，27(6)：975-984.
［12］Tang K，Zhang Y，Zhang H，et al.Delivery of chemotherapeutic drugs in tumour cell-derived microparticles［J］.Nat Commun，2012，3：1282.
［13］Untch M，Jackisch C，Schneeweiss A，et al.Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69)：A randomised，phase 3 trial［J］.Lancet Oncol，2016，17(3)：345-356.
［14］Sohal DP，Mangu PB，Khorana AA，et al.Metastatic pancreatic cancer：American society of clinical oncology clinical practice guideline［J］.J Clin Oncol，2016，34(23)：2784-2796.
［15］Li Y，Zeng J，Huang M，et al.A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced，recurrent，or metastatic cervical carcinoma［J］.Cancer，2017，123(3)：420-425.
［16］Carnevale J，Ko AH.MM-398(nanoliposomal irinotecan)：Emergence of a novel therapy for the treatment of advanced pancreatic cancer［J］.Future Oncol，2016，12(4)：453-464.
［17］Zhang H.Onivyde for the therapy of multiple solid tumors［J］.Onco Targets Ther，2016，9：3001-3007.
［18］Nevala WK，Buhrow SA，Knauer DJ，et al.Antibody-targeted chemotherapy for the treatment of melanoma［J］.Cancer Res，2016，76(13)：3954-3964.
［19］De Goeij BE，Lambert JM.New developments for antibody-drug conjugate-based therapeutic approaches［J］.Curr Opin Immunol，2016，40：14-23.
［20］Beck A，Goetsch L，Dumontet C，et al.Strategies and challenges for the next generation of antibody-drug conjugates［J］.Nat Rev Drug Discov，2017，16(5)：315-337.
［21］No authors listed.ADC shows effectiveness in SCLC［J］.Cancer Discov，2015，5(12)：OF4.
［22］Li J，Ren J，Sun W.Systematic review of ixabepilone for treating metastatic breast cancer［J］.Breast Cancer，2017，24(2)：171-179.
［23］Del Carmen MG，Supko JG，Horick NK，et al.Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent，platinum-sensitive ovarian，fallopian tube，or primary peritoneal cancer［J］.Cancer，2016，122(21)：3297-3306.
［24］Ratan R，Patel SR.Chemotherapy for soft tissue sarcoma［J］.Cancer，2016，122(19)：2952-2960.
［25］Martin-Broto J，Pousa AL，De Las Peas R，et al.Randomized phase Ⅱ study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas：A spanish group for research on sarcoma study［J］.J Clin Oncol，2016，34(19)：2294-2302.
［26］Borad MJ，Reddy SG，Bahary N，et al.Randomized phase Ⅱ trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer［J］.J Clin Oncol，2015，33(13)：1475-1481.
［27］Zhang BH, Yue HY. Precision chemotherapy for the treatment of cancers ［J］. Journal of International Oncology, 2017, 44（2）: 133-135.［张百红，岳红云.肿瘤的精准化疗［J］.国际肿瘤学杂志，2017，44（2）：133-135.］
［28］Gujral TS，Kirschner MW.Hippo pathway mediates resistance to cytotoxic drugs［J］.Proc Natl Acad Sci USA，2017，114(18)：E3729-E3738.
［29］Zhang Y，Fox JT，Park YU，et al.A Novel chemotherapeutic agent to treat tumors with DNA mismatch repair deficiencies［J］.Cancer Res，2016，76(14)：4183-4191.
［30］Gotwals P，Cameron S，Cipolletta D，et al.Prospects for combining targeted and conventional cancer therapy with immunotherapy［J］.Nat Rev Cancer，2017，17(5)：286-301.
［31］Lo CS，Sanii S，Kroeger DR，et al.Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy［J］.Clin Cancer Res，2017，23(4)：925-934.
［32］Wang W，Kryczek I，Dostál L，et al.Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer［J］.Cell，2016，165(5)：1092-1105.
［33］Sidaway P.CNS cancer：Local chemotherapy favours antitumour immunity［J］.Nat Rev Clin Oncol，2017，14(3)：138.
［34］Mathios D，Kim JE，Mangraviti A，et al.Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM［J］.Sci Transl Med，2016，8(370)：370ra180.
［35］Cardillo TM，Sharkey RM，Rossi DL，et al.Synthetic lethality exploitation by an anti-trop-2-SN-38 antibody-drug conjugate，IMMU-132，Plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer［J］.Clin Cancer Res，2017，23(13)：3405-3415.
［36］Heist RS，Guarino MJ，Masters G，et al.Therapy of advanced non-small cell lung cancer with an sn-38-anti-trop-2 drug conjugate，sacituzumab govitecan［J］.J Clin Oncol，2017，35(24)：2790-2797.
［37］Alexander JL，Wilson ID，Teare J，et al.Gut microbiota modulation of chemotherapy efficacy and toxicity［J］.Nat Rev Gastroenterol Hepatol，2017，14(6)：356-365.